Epitalon: Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 15 sources cited

Overview

Epitalon (Epithalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the natural pineal gland peptide epithalamin, developed by Russian gerontologist Professor Vladimir Khavinson over three decades of research. It is the most extensively studied telomerase-activating peptide, reported to lengthen telomeres in human cell cultures, raise evening melatonin in old monkeys, and extend maximum lifespan in some mouse and fruit fly studies. Epitalon occupies a unique position in anti-aging research as one of the few compounds with direct evidence of telomere elongation in human cell cultures.

Mechanism of Action

Epitalon's primary anti-aging mechanism centers on activation of telomerase, the ribonucleoprotein enzyme responsible for maintaining telomere length at chromosome ends. Telomeres are repetitive TTAGGG nucleotide sequences that protect chromosomal DNA during cell division; with each replication cycle, telomeres shorten by 50–200 base pairs. When telomeres reach a critical minimum length (~5 kilobases), the cell enters replicative senescence — it stops dividing and begins secreting pro-inflammatory cytokines (the senescence-associated secretory phenotype, or SASP). In cultured human cells, Epitalon activates the hTERT gene, which encodes the catalytic subunit of human telomerase reverse transcriptase. By upregulating hTERT expression, Epitalon enables cells to add telomeric repeats back onto chromosome ends, effectively resetting the replicative clock. An in vitro study on human fetal lung fibroblasts reported that Epitalon-treated cells made 10 extra divisions beyond the point where untreated cells stopped dividing. Beyond telomerase activation, Epitalon restores circadian melatonin secretion from the pineal gland. The pineal gland calcifies and loses function with age, reducing melatonin output — a key driver of age-related sleep disruption and antioxidant decline. Epitalon raised evening melatonin in old rhesus monkeys, and small studies report higher night melatonin in elderly people with reduced pineal function; it did not increase melatonin release from isolated rat pineal glands. This is significant because melatonin is not just a sleep hormone; it is a potent free radical scavenger that protects mitochondrial DNA from oxidative damage. Epitalon also modulates the expression of genes involved in antioxidant defense (superoxide dismutase, glutathione peroxidase), apoptosis regulation, and immune function. The developers propose that it raises interferon-gamma production in T cells, based on cell and animal work; this has not been tested in human trials. In aging female mice it also slowed the age-related loss of estrous cycling.

Epitalon Benefits: What the Research Shows

  • Khavinson and colleagues reported that Epitalon induced telomerase activity and telomere elongation in cultured human fetal fibroblasts, which normally lack telomerase (Bulletin of Experimental Biology and Medicine, 2003)
  • A 12-year randomized study in elderly coronary patients receiving epithalamin (the pineal extract Epitalon was modeled on, not Epitalon itself) reported 28% fewer deaths and 2-fold lower cardiovascular mortality than in controls (Bulletin of Experimental Biology and Medicine, 2006)
  • Anisimov et al. reported that Epitalon increased mean survival by 5.3% and lowered spontaneous tumor incidence in female CBA mice (Mechanisms of Ageing and Development, 2001); in female SHR mice it did not change mean lifespan but extended the lifespan of the longest-lived 10% by 13.3% (Biogerontology, 2003)
  • Studies in old rhesus monkeys found that a 10-day Epitalon course raised evening melatonin and restored the daily cortisol rhythm (Bulletin of Experimental Biology and Medicine, 2001)
  • A follow-up from the same group (Bulletin of Experimental Biology and Medicine, 2004) reported that Epitalon-treated human fetal lung fibroblasts made 10 extra divisions beyond the point where untreated cells stopped dividing
  • A small placebo-controlled study in women aged 40–50 working night shifts reported that sublingual Epitalon for 20 days raised urinary excretion of a melatonin metabolite 1.7-fold and shifted clock-gene expression; sleep itself was not measured (Advances in Gerontology, 2020)
  • Research in old rats found that Epitalon and the pineal extract epithalamin strengthened antioxidant defenses, including antioxidant enzyme activity (Archives of Gerontology and Geriatrics, 2007)
  • Peptide bioregulation studies by Khavinson showed Epitalon normalized chromatin structure in aged lymphocytes, reactivating previously silenced gene expression
  • Research in Drosophila melanogaster found that Epitalon given during the larval stage extended adult lifespan by 11–16% (Mechanisms of Ageing and Development, 2000)

Epitalon Dosage

  • Standard protocol: 5–10 mg subcutaneous injection daily for 10–20 consecutive days, repeated every 4–6 months
  • Published Khavinson-group human studies used much smaller doses than these community protocols: 0.01 mg IM daily for 10 days in elderly subjects, and about 0.5 mg per day sublingually for 20 days
  • Conservative protocol: 5 mg subcutaneous injection daily for 10 days every 6 months
  • Some practitioners use 1–3 mg daily for 20 days for a lower-dose, longer-duration approach
  • Inject in the evening (before bed) to align with natural melatonin secretion patterns
  • Intranasal formulation (na-epitalon): 1–3 sprays per nostril daily for 30 days
  • No loading phase required — effects are cumulative across treatment courses
  • Allow minimum 4 months between courses to assess telomere response
Peptide calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

Epitalon Side Effects & Safety

Known Side Effects

  • Injection site reactions: mild redness, swelling, or itching (common, transient, resolves within 1 hour)
  • Temporary flushing or warmth sensation immediately after injection, especially with higher doses
  • Mild headache during first 2–3 days of treatment course, reported by some users
  • Increased dream vividness and deeper sleep (often considered a positive effect of restored melatonin)
  • Rare: mild fatigue during the treatment course as circadian rhythms readjust
  • No published clinical study has assessed Epitalon's safety in humans; an FDA review found no clinical safety data and no adverse event reports in its databases as of December 2025

Safety Profile

Epitalon's safety in humans is not well documented. The published human studies are few and small, none was designed to assess safety, and a 2026 FDA review concluded there are no clinical data to support its safety in humans. The 12- and 15-year follow-up studies in elderly coronary patients tested the pineal extract epithalamin, not Epitalon; they reported lower mortality in the treated group, which cannot be assumed to carry over to the synthetic peptide. Whether telomerase activation by Epitalon carries cancer risk is unknown. The short treatment courses (10–20 days) followed by months-long breaks are assumed, not shown, to limit that risk. Mouse and rat studies from the developers' group found fewer or unchanged tumors, but FDA judged them too limited to rule out carcinogenic potential, no standard 2-year carcinogenicity study exists, and one cell study found Epitalon also lengthened telomeres in breast cancer cell lines. Contraindications are minimal: avoid during active cancer treatment (theoretical concern about telomerase in malignant cells), pregnancy, and breastfeeding. Drug interactions have not been studied, and long-term safety in humans has not been established.

What to Expect

Days 1–5: Users commonly report improved sleep quality and faster sleep onset within the first few days; no study has measured sleep outcomes with Epitalon. Energy levels may fluctuate as circadian rhythms readjust. Days 5–10: Deeper, more restorative sleep becomes consistent. Many report improved morning alertness and reduced daytime fatigue. Some users note improved skin texture and appearance, though this has not been studied in people. Weeks 2–8 post-course: Any longer-term anti-aging effect is unproven: telomerase activation and telomere lengthening have been shown in cultured cells, not in published studies of people taking Epitalon. Improved immune function, better stress resilience, and sustained sleep quality improvements are commonly reported. Subsequent courses (4–6 months later): Each treatment course builds on previous gains. Long-term users report sustained vitality improvements, better skin quality, improved cognitive clarity, and a general sense of biological age reversal. No published human study has measured telomere length after Epitalon treatment, so what such measurements would show is unknown.

Common Stacks

Storage & Handling

Store lyophilized Epitalon at -20°C for maximum stability (up to 36 months) or 2–8°C (refrigerated) for up to 12 months. Epitalon is relatively stable compared to larger peptides due to its small tetrapeptide structure. Reconstitute with bacteriostatic water — add 1 mL per vial for convenient dosing. Once reconstituted, store at 2–8°C; supplier data cited by FDA put stability in solution at only 2–7 days at 4°C, so use it promptly or freeze portions. Protect from light. The reconstituted solution should be clear and colorless; discard if cloudy or discolored.

Pricing & Available Variants

$120price range
10mg50mg

Prices sourced from peptides.gg marketplace. Prices may vary.

References

  1. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026: Epitalon-Related Bulk Drug Substances (Epitalon (Free Base) and Epitalon Acetate). U.S. Food and Drug Administration. 2026.
  2. Jain A, Gallacher DM, Issa MA, et al. Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence. Int J Mol Sci. 2026.
  3. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003.
  4. Khavinson VKh, Bondarev IE, Butyugov AA, et al. Peptide promotes overcoming of the division limit in human somatic cell. Bull Exp Biol Med. 2004.
  5. Al-Dulaimi S, Thomas R, Matta S, et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025.
  6. Anisimov VN, Khavinson VK, Mikhalski AI, et al. Effect of synthetic thymic and pineal peptides on biomarkers of ageing, survival and spontaneous tumour incidence in female CBA mice. Mech Ageing Dev. 2001.
  7. Anisimov VN, Khavinson VKh, Popovich IG, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003.
  8. Khavinson VK, Izmaylov DM, Obukhova LK, et al. Effect of epitalon on the lifespan increase in Drosophila melanogaster. Mech Ageing Dev. 2000.
  9. Goncharova ND, Khavinson BK, Lapin BA. Regulatory effect of Epithalon on production of melatonin and cortisol in old monkeys. Bull Exp Biol Med. 2001.
  10. Korkushko OV, Lapin BA, Goncharova ND, et al. Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people. Adv Gerontol. 2007.
  11. Ivko OM, Linkova NS, Ilina AR, et al. AEDG peptide regulates human circadian rhythms genes expression during pineal gland accelerated aging. Adv Gerontol. 2020.
  12. Korkushko OV, Khavinson VKh, Shatilo VB, et al. Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bull Exp Biol Med. 2006.
  13. Korkushko OV, Khavinson VKh, Shatilo VB, et al. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bull Exp Biol Med. 2011.
  14. Khavinson VKh, Lezhava TA, Monaselidze JR, et al. Peptide Epitalon activates chromatin at the old age. Neuro Endocrinol Lett. 2003.
  15. Kozina LS, Arutjunyan AV, Khavinson VKh. Antioxidant properties of geroprotective peptides of the pineal gland. Arch Gerontol Geriatr. 2007.

Related Peptides

Track Epitalon in Your Protocol

Log your Epitalon doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free